Pharming Group
Update in progressPHAR (NasdaqGM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Pharming Group N.V. is a biopharmaceutical company that develops and commercializes protein replacement therapies and precision medicines for rare diseases in the United States, Europe, and globally. Its lead product is RUCONEST, a recombinant C1 esterase inhibitor for acute attacks of hereditary angioedema in adults and adolescents. It also develops Joenja (leniolisib), an oral PI3K delta inhibitor for Activated PI3K Delta Syndrome. It has a collaboration with Novartis. Founded in 1988, it is headquartered in Leiden, the Netherlands.
Company score
- Sentiment
- 0.53
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.70
- Governance
- 0.14
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.24
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.38
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Company
- MarketNasdaqGM (NGM)
- LocationNetherlands
- CEOMr. Fabrice Chouraqui M.B.A., Ph.D., Pharm.D.
- Founded1988
- Employees407
- Websitewww.pharming.com
Identifiers
- ISINUS71716E1055
- FIGIBBG00YN70VB3
- CIK0001828316